Multidisciplinary management of non small cell lung cancer (NSCLC) in stage III: clinical case description. Recommendations and state of the art

Simona Carnio, Giulia Courthod, Simonetta Grazia Rapetti, Tiziana Vavalà, Matteo Giaj Levra, Enrica Capelletto, Silvia Novello

DOI: https://doi.org/10.7175/cmi.v7i1.632

Abstract

Lung cancer is the leading cause of cancer death in industrialized countries with progressive increase of its mortality rate. Non Small Cell Lung Cancer (NSCLC ) is approximately 80-85% of all lung cancers, being adenocarcinoma and squamous cell carcinoma the most common histologies. The majority of the patients with stage III clinical stage, presents a mediastinal lymph node involvement described with computed tomography (TC) and/or positron emission tomography (PET). The current approach to patients with NSCLC is multidisciplinary, especially for those staged as potentially operable, both for staging and for a correct definition of best treatment strategy. Updated international and national Guidelines and recommendations can provide valuable support to the clinician.

The case described concerns the accidental detection of a tumour in the lung in a 58-year-old man with arterial hypertension controlled with ACE inhibitors. The treatments agreed after a multidisciplinary approach are cisplatin and docetaxel, the surgical resection, and the radiotherapy. After three months the patient has neither metastasis nor relapse.

Keywords

Non small cell lung cancer; Multidisciplinary management; Stage III disease; Therapy

Full Text

HTML PDF

References

  • Jemal A, Bray F, Center MM ,et al “ Global cancer statistics ”. CA Cancer J Clin 2011; 61:69-90
  • Ferlay J, Parkin DM, Steliarova-Foucher E, “Estimates of cancer incidence and mortality in Europe in 2008”. Eur J Cancer. 2010 Mar;46(4):765-81
  • Malvezzi M, Bertuccio P, Levi F et al, “ European cancer mortality predictions for year 2012”. Ann. Oncol 2012; 23: 1044-1052”
  • Dati del Reparto di Epidemiologia dei Tumori del Centro Nazionale di Epidemiologia Sorveglianza e Promozione della Salute dell’Istituto Superiore di Sanità
  • Mountain CF, Dresler CM, “ Regional Lymph node classification for lung cancer staging ”. Chest 1997; 11:1718-1723
  • Rusch VW, Asamura H, Watanabe H and Members of IASLC Staging Committee, “The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer ”, J Thorac Oncol. 2009 May;4(5):568-77.
  • Goldstraw P, Crowley J, Chansky K, et al “The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours ”, J Thorac Oncol. 2007 Aug;2(8):706-14
  • Eisenhauer E.A, Therasse P, Bogaerts J, et al “New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)”,European Journal of Cancer, 2009; 228-247
  • Burt ME, Pomerantz AH, Bains MS, et al “ Results of surgical treatment of stage III lung cancer invading the mediastinum ”. Surg Clin North Am 1987; 67:987-1000
  • Scagliotti GV, Pastorino U, Vansteenkiste JF, et al “ Preliminary results of C.H.E.S.T: a phase III randomized study of surgery alone or surgery plus pre-operative gemcitabine-cisplatin in early stages NSCLC. Follow-up data of CHEST trial ”, J Clin Oncol 2008; 25:399s
  • Douillard JY, Rosell R, De Lena M, et al “ Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non small cell lung cancer ( Adjuvant Navelbine International Trialist Association [ ANITA ] ): a randomized controlled trial ”, Lancet Oncol 2006;7:719-727
  • Scagliotti GV, Fossati R, Torri V, et al “ Randomized study of adjuvant chemotherapy for completely resected stage I, II o IIIA non small cell lung cancer ”. J Natl Cancer Inst 2003; 95:1453-1461
  • Burdett S, Stewart LA, Rydzewska L “ A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non small cell lung cancer ”, J Thorac Oncol 2006; 1:611-621
  • Albain KS, Swann RS, Rusch VW, et al “ Radiotherapy plus chemotherapy with or without surgical resection for stage III non small cell lung cancer : a phase III randomized controlled trial ”, Lancet 2009; 374:379-386
  • AIOM, Linee Guida neoplasie del polmone, 2012, pag:28-30; Disponibile all’indirizzo: http:// www.aiom.it
  • Huber RM et al, “Simultaneous chemoradiotherapy compared with radiotherapy aloneafter induction chemotherapy in inoperabile Stage IIIA or IIIB NSCLC ”, J Clin Oncol 2006;24:4397-4404
  • Mc Caughan BC, et al “ Primary lung cancer invading the chest wall ”, Chest Surg Clin North Am. 1994; 4:17-28
  • AIOM, Linee Guida neoplasie del polmone, 2012, pag:15; Disponibile all’indirizzo: http:// www.aiom.it
  • Silvestri GA, Gould MK, Margolis ML et al “ Noninvasive staging of non small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) ”, Chest 2007; 132:178S-201S
  • Detterbeck FC, Jantz MA, Wallance M, et al “ Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines ( 2nd edition ) ”, Chest 2007; 132: 202S-220S
  • Kiser AC, Detterbeck FC “ General aspects of surgical treatment ” In: Detterbeck FC. Rivera MP. Socinski MA, et al, eds “ Diagnosis and treatment of lung cancer: an evidence based guide for the practicing clinician ”. Philadelphia, PA: WB Saunders, 2001¸pg. 133-147
  • Gilligan D, Nicolson M, Smith I,et al “Preoperative chemotherapy in patients with resectable non small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review ”, Lancet 2007;369:1929-1937
  • Poldermans D, Jeroen J. Bax, Boersma E, “Linee Guida per la valutazione preoperatoria del rischio cardiaco e la gestione perioperatoria del paziente cardiopatico nella chirurgia non cardiaca ”, G Ital Cardiol 2010; 11 (10 Suppl 2): e136-e181
  • Valutazione preoperatoria del paziente da sottoporre a chirurgia elettiva, Linee guida nazionali di riferimento, Luglio 2005
  • Azzolina R, Cantarella G, La Camera G, “The spirometric examination how mean diagnostic pre-operating for appraising the functional respiratory reserves, the possibilities of remuneration and the anesthesiological risk in the patients with severe BPCO”, Acta Medica Mediterranea, 2010, 26: 67
  • Celli BR, Cote CG, Marin JM, et al “The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease ”, N Engl J Med. 2004; 350:1005-12
  • Boffa DJ, Allen MS, Grab JD, et al “ Data from the Society of Thoracic Surgeons, General Thoracic Surgery Database: The surgical management of primary lung tumors ”, J Thorac Cardiovas Surg 2008 Feb;135:247-54
  • Perrot E, Guibert B, Mulsant P, et al “ Preoperative chemotherapy does not increase complications after non small cell lung cancer resection ”, Ann Thorac Surg 2005; 80:423-427
  • Brunelli A, Xiumé F. Refai MA, et al “ Gemcitabine-cisplatin chemotherapy before lun resention: a case-matched analysis of early outcome ” Ann Thorac Surg 2006; 81:1963-1968
  • Venuta F, Anile M, Diso D, et al “ Operative complications and early mortality after induction therapy for lung cancer ”, Eur J Cardiothorac Surg 2007;31: 714-718
  • Felip E, Rosell R, Maestre JA, et al “ Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non small cell lung cancer ”, J Clin Oncol 2010; 28:3138-3145
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), “ Non Small Cell Lung Cancer ”version 3.2012; Disponibile all’indirizzo: http:// www.nccn.com
  • AIOM,” Linee Guida Neoplasia Polmone 2012”; Disponibile all’indirizzo: http:// www.aiom.it
  • Doddoli C, Barlesi F, Trousse D, et al “ One hundred consecutive pneumonectomies after induction therapy for non small cell lung cancer: an uncertain balance between risks and benefits ”, Thorac Cardiovasc Surg 2005; 130:416-425t
  • Cho GH, Kim J, Kim K, et al “ Risk associated with bilobectomy after neoadjuvant concurrent chemoradiotherapy for stage IIIA-N2 non-small-cell lung cancer”, World J Surg. 2012 May;36(5):1199-205
  • Pisters KMW, Evans WK, Azzoli CG, et al “Cancer care Ontario and American Society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small cell lung cancer guideline ”, J Clin Oncol 2007;25:5506-5518
  • Crinò L,Weder W,van Meerbeeck J, et al “ Early stage and locally advanced (non metastatic) non small cell lung cancer: ESMO Clinical Practise Guidelines for diagnosis, treatment and follow-up ”, Ann Oncol 2010;21(Suppl 5):v103-v115
  • AIOM, Linee Guida neoplasie del polmone, 2012, 25-32; Disponibile all’indirizzo: http:// www.aiom.it
  • Gandara DR, Chansky K, “ Long term survival with concurrent chemoradiation therapy followed by consolidan docetaxel in stage IIIB NSCLC: a phase II Southwest Oncology Group Study ( S9504 )”, Clin Lung cancer 2006; 08:116-121
  • AIOM, Linee Guida neoplasie del polmone, 2012, 32-33; Disponibile all’indirizzo: http:// www.aiom.it
  • Albain KS, Crowley JJ, Turrisi AT 3rd, “ Concurrent cisplatin, etoposide anch chest radiotherapy in pathologic stage IIIB NSCLC: a southwest Oncology Group phase II study, SWOG 9019 ”, J Clin Oncol 2002; 20:3454-3460
  • Socinski MA, Stinchcombe TE, Moore DT, et al “ Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non-Small-Cell Lung Cancer: Results of a Phase I/II Trial ”, J Clin Oncol. 2012 Nov 10;30(32):3953-9
  • Hallqvist A, Bergman B, Nyman J, “ Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials ”. Radiother Oncol. 2012 Jul;104(1):39-44.
  • Vokes EE, Senan S, Treat JA, et al “ PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology ”, Clin Lung Cancer.2009 May;10(3):193-8
  • Gandara DR, Chansky K. Long term survival with concurrent chemo-radiation therapy followed by consolidan docetaxel in stage IIIB NSCLC: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006; 08: 116-21
  • Albain KS, Crowley JJ, Turrisi AT 3rd. Concurrent cisplatin, etoposide anch chest radiotherapy in pathologic stage IIIB NSCLC: a southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20: 3454-60
  • Socinski MA, Stinchcombe TE, Moore DT, et al. Incorporating bevacizumab and erlotinib in
  • the combined-modality treatment of stage III Non-Small-Cell Lung Cancer: results of a phase
  • I/II trial. J Clin Oncol 2012; 30: 3953-9
  • Hallqvist A, Bergman B, Nyman J. Health related quality of life in locally advanced NSCLC
  • treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results
  • from two prospective clinical trials. Radiother Oncol 2012; 104: 39-44
  • Vokes EE, Senan S, Treat JA, et al. PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009; 10: 193-8

Statistics

Abstract: 1400 views
HTML: 3572 views
PDF: 446 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.